Abcam Joins Innovative Health Initiative LIGAND-AI Project to Advance AI-Driven Drug Discovery

Abcam joined the LIGAND-AI project on January 20, 2026, as part of an 18-partner consortium led by Structural Genomics Consortium and Pfizer.1 2

LIGAND-AI, funded by the Innovative Health Initiative with over €60 million budget, aims to generate large, high-quality open protein-ligand datasets for training AI models to predict binders for thousands of human proteins over five years.1 2

Abcam contributes expertise in recombinant protein engineering, synthesis, and production to enable robust ligand-binding datasets.1 2

The project targets diseases including rare, neurological, and oncological conditions, aligning with Target 2035's goal of chemical modulators for every human protein by 2035, with data shared under FAIR principles.1 2

Partners span nine countries, including academia (e.g., European Molecular Biology Laboratory, University College London), industry (e.g., AstraZeneca, Novo Nordisk), and tech (e.g., IBM).1 2

Sources:

1. https://www.prnewswire.com/news-releases/abcam-joins-the-innovative-health-initiative-ligand-ai-project-to-advance-artificial-intelligence-ai-driven-drug-discovery-through-open-science-302665355.html

2. https://www.moomoo.com/news/post/64291825/abcam-joins-the-innovative-health-initiative-ligand-ai-project-to

Sources:

Leave a Reply Cancel reply